Replimune Group (NASDAQ:REPL) Director Kapil Dhingra Sells 21,500 Shares of Stock

Replimune Group, Inc. (NASDAQ:REPL) Director Kapil Dhingra sold 21,500 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $19.00, for a total transaction of $408,500.00. Following the completion of the sale, the director owned 21,669 shares of the company’s stock, valued at approximately $411,711. This represents a 49.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Trading Up 6.0%

Shares of REPL opened at $20.65 on Wednesday. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59. The company has a 50 day moving average price of $13.79 and a 200-day moving average price of $9.47. Replimune Group, Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $21.26.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.24. As a group, research analysts forecast that Replimune Group, Inc. will post -2.40 EPS for the current year.

Hedge Funds Weigh In On Replimune Group

Institutional investors and hedge funds have recently bought and sold shares of the company. Essential Partners LLC lifted its holdings in shares of Replimune Group by 562,400.0% during the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after purchasing an additional 5,624 shares during the last quarter. Allworth Financial LP purchased a new position in Replimune Group during the 2nd quarter worth $62,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Replimune Group during the 3rd quarter worth $64,000. Legal & General Group Plc acquired a new position in Replimune Group during the 2nd quarter valued at about $85,000. Finally, WINTON GROUP Ltd acquired a new position in Replimune Group during the 2nd quarter valued at about $115,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on REPL shares. Wall Street Zen raised Replimune Group from a “sell” rating to a “hold” rating in a research report on Saturday. Leerink Partners raised their price objective on Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a research report on Thursday, October 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. Weiss Ratings lowered Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Finally, Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.33.

Replimune Group Company Profile

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.